| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Serine/threonine-protein kinase DCLK3; EC 2.7.11.1; Doublecortin-like and CAM kinase-like 3; Doublecortin-like kinase 3; DCLK3 |
| Entrez GeneID | 85443; |
| WB Predicted band size | 74kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human DCLK3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DCLK3抗体的假设性参考文献示例(请注意，部分内容可能基于真实研究的推测，具体文献需通过学术数据库核实)：
---
1. **文献名称**: *"Characterization of DCLK3-Specific Monoclonal Antibodies for the Study of Pancreatic Cancer Progression"*
**作者**: Zhang, L., et al. (2021)
**摘要**: 本研究开发了一种高特异性抗DCLK3单克隆抗体，并通过免疫印迹和免疫组化验证其在胰腺癌组织中的反应性，证实DCLK3在肿瘤干细胞中的表达与转移相关。
2. **文献名称**: *"DCLK3 Antibody Validation in Neuroblastoma: Implications for Therapeutic Targeting"*
**作者**: Patel, R., & Kumar, S. (2019)
**摘要**: 通过比较多种商业DCLK3抗体的特异性，筛选出适用于神经母细胞瘤模型的抗体，并证明DCLK3抑制可减少肿瘤细胞增殖。
3. **文献名称**: *"DCLK3 Isoforms and Antibody Cross-Reactivity in Glioblastoma Studies"*
**作者**: Müller, T., et al. (2020)
**摘要**: 分析了DCLK3抗体在胶质母细胞瘤中的交叉反应性，发现部分抗体与DCLK家族其他成员存在交叉反应，强调了抗体验证的重要性。
4. **文献名称**: *"A Novel Anti-DCLK3 Antibody Modulates Wnt/β-Catenin Signaling in Colorectal Cancer"*
**作者**: Chen, Y., et al. (2022)
**摘要**: 报道了一种新型兔源多克隆抗体的开发，证实其通过抑制DCLK3-Wnt通路活性减缓结直肠癌细胞生长。
---
**说明**：
- DCLK3相关抗体研究多集中于癌症(如胰腺癌、神经母细胞瘤)和信号通路机制。
- 实际文献需通过PubMed、Web of Science等平台，以“DCLK3 antibody”、“DCLK3 validation”等关键词检索。
- 部分商业抗体供应商(如Abcam、CST)的技术文档可能提供引用文献。
建议结合具体研究需求进一步筛选和验证文献可靠性。
The DCLK3 (Doublecortin-like kinase 3) antibody is a tool used to study the DCLK3 protein, a member of the doublecortin domain-containing protein kinase family. DCLK3. encoded by the *DCLK3* gene, is characterized by its dual N-terminal doublecortin (DCX) domains and a C-terminal serine/threonine kinase domain. It plays roles in microtubule stabilization, neuronal development, and cellular processes like mitosis and migration. Unlike its homologs DCLK1 and DCLK2. DCLK3 is less studied but shares structural and functional similarities, including involvement in neurogenesis and cancer progression.
Research suggests DCLK3 is expressed in specific tissues, including the brain, and may contribute to tumorigenesis by regulating cancer stem cells or epithelial-mesenchymal transition (EMT). Its kinase activity and interaction with microtubules make it a potential therapeutic target in neurological disorders and cancers. The DCLK3 antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and post-translational modifications. Validation of antibody specificity is critical due to homology among DCLK family members. Recent studies explore its role as a biomarker or target in diseases, though further functional characterization is needed to clarify its mechanisms and therapeutic potential.
×
